<DOC>
	<DOCNO>NCT00003715</DOCNO>
	<brief_summary>RATIONALE : Vaccines make person 's melanoma cell may make body build immune response kill tumor cell . Interferon alfa may interfere growth cancer cell . PURPOSE : Randomized phase III trial compare effectiveness melanoma vaccine interferon alfa-2b treating patient stage III melanoma spread regional lymph node follow surgery .</brief_summary>
	<brief_title>Vaccine Therapy Compared With Interferon Alfa Treating Patients With Stage III Melanoma</brief_title>
	<detailed_description>OBJECTIVES : I . Compare relapse-free overall survival rate patient stage III melanoma treat autologous tumor vaccine versus interferon alfa-2b postsurgical adjuvant therapy . II . Compare safety tolerability regimens patient population . OUTLINE : This randomize , open-label , multicenter study . Patients stratify accord number metastatic lymph node site ( 1 vs 1 ) , number positive lymph node single site ( none vs 1 ) , presence intransit metastasis ( yes v ) , evidence extranodal extension ( yes v ) . Patients randomize one two treatment arm . Arm I : Patients receive autologous tumor cell vaccine intradermally week 7 week follow booster injection 6 month . BCG give concurrently vaccine immune-stimulator dos 2-8 . Patients also receive cyclophosphamide 6 day first vaccine injection . Arm II : Patients receive interferon alfa-2b IV 5 consecutive day week 4 week follow maintenance dos give subcutaneously 3 time week 48 week . Patients follow monthly 1 year , every 2 month 1 year , every 3 month 1 year , every 6 month 2 year . PROJECTED ACCRUAL : A total 386-425 patient accrue study .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>BCG Vaccine</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm melanoma metastatic regional lymph node clinically palpable mass Must clinical evidence follow : Metastases 1 nodal site All node microscopically negative No intransit metastases No extranodal extension OR Metastases 1 nodal site More 1 positive lymph node single site Intransit metastases Extranodal extension Must undergone complete resection tumor , measure least 2 cm diameter , within past 6 week No distant metastases PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 80100 % Life expectancy : At least 6 month Hematopoietic : Hematocrit least 30 % WBC least 3,000/mm3 Hepatic : Hepatitis B C negative Renal : Not specify Other : Not pregnant nursing No active serious infection No active autoimmune disease HIV negative No malignancy within last 5 year except squamous cell carcinoma skin , carcinoma situ cervix , superficial bladder carcinoma , early stage prostate cancer , noninvasive melanoma No active severe depression psychiatric disorder psychotic symptoms No uncontrolled thyroid abnormality PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : At least 6 week since prior cytotoxic drug ( except isolate limb perfusion ) Endocrine therapy : No concurrent systemic corticosteroid Radiotherapy : At least 6 month since prior radiotherapy Surgery : See Disease Characteristics Other : At least 30 day since prior investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>stage III melanoma</keyword>
</DOC>